MDR-TB

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance

Retrieved on: 
星期三, 四月 24, 2024
TST, Genetically modified bacteria, WHO, Virtual reality, CDC, Multidrug-resistant tuberculosis, Bacteria, AMR, ESCMID, QIAGEN, ECCMID, MDR-TB, WGS, Doctor of Philosophy, Research, Workflow, Sputum, NGS, PCR, Disease, Patient, Panel, Mycobacterium tuberculosis, QGEN, Gold, Infection, D20, Emerging, Tuberculosis, Cerebrospinal fluid, Vaccine

The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).

Key Points: 
  • The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).
  • By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
  • “The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN.
  • The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment.

Yes! We Can End TB & AIDS, Says AHF

Retrieved on: 
星期五, 三月 22, 2024
White House, Federal Government, Public Policy, Other Health, General Health, Women, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Men, LGBTQ+, Foundation, Other Philanthropy, AIDS, Consumer, Health, Coinfection, AIDS Healthcare Foundation, Tuberculosis, World Tuberculosis Day, HIV, Global health, Education, Death, Infection, World Health Organization, Multidrug-resistant tuberculosis, TB, MDR-TB, AHF, Multimedia, Pharmaceutical industry

We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.

Key Points: 
  • We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.
  • View the full release here: https://www.businesswire.com/news/home/20240322482439/en/
    AIDS Healthcare Foundation (AHF) country teams, which have prioritized screening for TB in clinics—along with preventing and treating HIV/TB co-infection—will hold World TB Day commemorations around the globe.
  • Integrating TB prevention and care into HIV programs, which AHF has done, is essential for comprehensive healthcare.
  • We Can End TB & AIDS.’”
    According to the World Health Organization, TB claimed 1.3 million lives in 2022, including 167,000 people living with HIV, with an estimated nearly 11 million people falling ill to TB worldwide.

Latent Tuberculosis Testing Market Set to Reach $1.96 Billion in 2023 with a CAGR of 5.95% - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 23, 2023
Health, Infectious Diseases, LTBI, Ageing, MDR-TB, Acid test (gold), NAAT, Tuberculosis, Johnson & Johnson Pharmaceutical Research and Development, TB, Prevalence, HIV, Urbanization, Research, Spectroscopy, Smoking, Smoker, Trendsetter, Growth, Immune system, COVID-19, Risk, Hospital, Pharmacy, Investment, Diagnosis, IGRA, Tobacco, Infection, Pharmaceutical industry, Vaccine, Fine chemical, Medical imaging, Tuberculin

Latent tuberculosis, a condition where tuberculosis bacteria remain dormant within the body, presents a unique challenge in healthcare.

Key Points: 
  • Latent tuberculosis, a condition where tuberculosis bacteria remain dormant within the body, presents a unique challenge in healthcare.
  • By Type: The LTBI testing market is segmented into Tuberculin skin test LTBI testing and interferon gamma released assay (IGRA).
  • Geographic Coverage: The global LTBI testing market spans North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
  • The global LTBI testing market features a moderately fragmented landscape, with numerous small- and medium-sized manufacturers contributing significantly.

AHF Slams Johnson & Johnson for Immoral Profiteering on TB Treatment

Retrieved on: 
星期二, 九月 19, 2023
Medical Supplies, AIDS, Other Health, Health, General Health, Public Policy, Pharmaceutical, Other Policy Issues, Infectious Diseases, Government, Advocacy Group Opinion, AHF, Bedaquiline, TB, Medicine, Death, Multidrug-resistant tuberculosis, Patent, Tuberculosis, AIDS Healthcare Foundation, MDR-TB, Johnson & Johnson, Pharmaceutical industry

The AIDS Healthcare Foundation (AHF) today strongly condemned pharma giant Johnson & Johnson (J&J) for again putting profits before people’s lives by charging South Africa more than twice what many other countries are paying for the multidrug-resistant tuberculosis (MDR-TB) medicine SIRTURO (bedaquiline) and extending its patent another four years.

Key Points: 
  • The AIDS Healthcare Foundation (AHF) today strongly condemned pharma giant Johnson & Johnson (J&J) for again putting profits before people’s lives by charging South Africa more than twice what many other countries are paying for the multidrug-resistant tuberculosis (MDR-TB) medicine SIRTURO (bedaquiline) and extending its patent another four years.
  • “While shocking, this move by Johnson & Johnson is unfortunately not surprising – we demand that the company halt its profiteering tactics immediately and sell South Africa bedaquiline at the same cost countries are paying through Stop TB Partnership’s Global Drug Facility .
  • Additionally, J&J must avail the patent for the lifesaving treatment so that generic drug manufacturers can produce the medicine at affordable prices,” said Dr. Kate Ssamula, Country Program Director for AHF South Africa.
  • “We have one of the highest rates of MDR-TB globally, and tuberculosis is the leading cause of death for South Africans, with 56,000 TB deaths in 2021 alone.

Global Latent Tuberculosis Infection (LTBI) Testing Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
星期二, 十月 4, 2022
Health, COVID-19, Other Science, Clinical Trials, General Health, Science, Movement, Tuberculosis, Cancer, Company, Preventive healthcare, Non-functional testing, Spectroscopy, LabCorp, Prevalence, Infection, TST, Naʽat, Disulfiram-like drug, MDR-TB, CAGR, IGRA, Center, COVID-19, Institutionalisation, Ageing, Health, Immune system, Growth, LTBI, HIV, Pharmacy, Bacteria, TB, Immunosuppression, CDC, Patient, Diagnosis, Risk, Interferon, Urbanization, Cdx, Centers for Disease Control and Prevention timeline, Population, Pharmaceutical industry, Vaccine, Tobacco, Medical device, Fine chemical, Heating, ventilation, and air conditioning

The "Global Latent Tuberculosis Infection (LTBI) Testing Market: Analysis By Type (Tuberculin Skin Test LTBI Testing and Interferon Gamma Released Assay (IGRA) LTBI Testing), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Latent Tuberculosis Infection (LTBI) Testing Market: Analysis By Type (Tuberculin Skin Test LTBI Testing and Interferon Gamma Released Assay (IGRA) LTBI Testing), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global latent tuberculosis infection (LTBI) testing market in 2021 was valued at US$1.75 billion and is expected to reach US$2.47 billion by 2027, growing at a CAGR of 5.95% during 2022-2027.
  • One of the most important factors impacting the global latent tuberculosis infection (LTBI) testing market is aging population.
  • As the aging population grows further, the risk of latent tuberculosis prevalence among them also tends to increase, which is expanding the scope for the growth of the global latent tuberculosis infection testing market in coming years.

Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline

Retrieved on: 
星期一, 八月 9, 2021
Pharmaceutical, Health, Clinical Trials, Health, Mouse, Creativity, OAPI, Union, Mycobacterium tuberculosis, Safety, Bill & Melinda Gates Foundation, Nephrology, CEO, Cardiology, Gates, Adult, LinkedIn, Overalls, Tuberculosis, Twitter, European Union, Ethambutol, Bill, MDR-TB, TB, Mortality, Maintenance, Medication, Patient, Melinda Gates, Multidrug-resistant tuberculosis, Isoniazid, Heart, Commercialization, Pyrazinamide, Mental health, Pharmaceutical industry, Silviculture, OPC-167832, delamanid (DELTYBA), Otsuka, OPC-167832, DELAMANID (DELTYBA), OTSUKA

Data gathered from this landmark trial will hopefully improve current management of TB and improve patient adherence by significantly shortening the duration of treatment.

Key Points: 
  • Data gathered from this landmark trial will hopefully improve current management of TB and improve patient adherence by significantly shortening the duration of treatment.
  • In 2017, Otsuka completed a phase 1, single-ascending-dose study of OPC-167832.
  • The phase 2 trial of OPC-167832, delamanid (DELTYBA) and bedaquiline (SIRTURO) is expected to begin in 2022 with results available in 2024.
  • Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.